Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01476982
Other study ID # EPIC-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received October 28, 2011
Last updated March 18, 2013
Start date May 2012

Study information

Verified date March 2013
Source Epic Research & Diagnostics, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

The primary objective of this feasibility study is to determine whether it is possible to conduct a study of the ClearView scan among patients under evaluation for acute cardiovascular events, as well as give insight into the performance of the ClearView scoring algorithm with respect to this patient population. The EPICâ„¢ scan is a bio-electrographic tool that may assist the health care provider in rapid assessment of the systemic origin of the patient's presenting symptom(s). The EPIC ClearView is a potentially valuable resource that may benefit an emergency department (ED) by offering expedited "chest pain" etiologic differentiation capabilities. The subsequent results have the potential to include more rapid "chest pain" patient diagnosis and appropriate disposition of non-cardiac chest pain (rule out MI); optimized precious resource expenditure (nursing, physician, inpatient or observation bed, etc.); lower costs to facility, patient and insurance company; and greater patient satisfaction rates due to decreased ED wait time.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 200
Est. completion date
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

1. Sex: Male or Female

2. Age range: 18 to 85

3. Chief complaint upon admission to the ED: chest pain

4. The patient or legal representative is able to understand and provide signed consent for the procedure.

5. Every effort will be given to balance subjects by gender, age, and race.

Exclusion Criteria:

1. Patients < 18 years in age or > 85 years in age.

2. Inability or unwillingness to provide informed consent.

3. Patients with pacemakers or another electrical device, such as an automatic internal cardiac defibrillator, implanted somewhere in their body.

4. Patients connected to an electrical device that cannot be removed (i.e. monitor).

5. Pregnant women.

6. Patients currently undergoing therapy for cancer of any kind.

7. Patients missing all or part of any of their fingers.

8. Patients with hand tremors or involuntary oscillations ("shaking") of the hands that prevent clear imaging.

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Intervention

Device:
ClearView Scan
Assessment with ClearView device

Locations

Country Name City State
United States Scottsdale Healthcare Osborn Campus Scottsdale Arizona
United States Scottsdale Healthcare Shea Campus Scottsdale Arizona

Sponsors (2)

Lead Sponsor Collaborator
Epic Research & Diagnostics, Inc. Scottsdale Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Agreement of ClearView scan versus Active (Presenting) Diagnosis Statistical agreement will be assessed between the 0-25 ClearView Response Scale and the presenting diagnosis/diagnoses for the Emergency Department admission recorded within the medical record, on a per-subject basis. At time of study scan (Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit.) No